COPD Management with LABA and LAMA

Introduction to COPD Treatment

The Canadian Thoracic Society strongly recommends against ICS monotherapy in all patients with stable COPD at low risk of exacerbations, citing increased risk of adverse events without improvements in symptoms, exercise tolerance, or health status 1
When ICS is indicated in COPD, it should only be administered as part of combination therapy with long-acting bronchodilators, as recommended by the Canadian Thoracic Society 1, 3

LABA monotherapy is acceptable in patients with low exacerbation risk (≤1 moderate exacerbation in the last year without hospital admission), as suggested by guidelines from the European Respiratory Journal 1
Patients with moderate symptoms (CAT ≥10, mMRC ≥2) and FEV1 ≥50% predicted may be considered for LABA monotherapy, according to the European Respiratory Journal 4, 5
Multiple European national guidelines, including those from Finland, Poland, Portugal, Russia, and Spain, support LABA as an option for GOLD Group B patients (symptomatic, low exacerbation risk) 4, 5

LAMA monotherapy is preferred over LABA monotherapy for preventing exacerbations, with a strong recommendation from the ERS/ATS guideline based on moderate quality evidence 2
LAMA monotherapy reduces moderate-to-severe exacerbations (risk ratio 0.77, 95% CI 0.66-0.90) and severe exacerbations requiring hospitalization, and improves FEV1 (mean difference +19 mL), as reported by the European Respiratory Journal 2
LAMA/LABA dual therapy is recommended for patients with moderate-to-high symptom burden and impaired lung function (FEV1 <80% predicted), according to the Canadian Thoracic Society 1

For symptomatic patients (Group B), first-line treatment is LAMA monotherapy or LAMA/LABA dual therapy, as recommended by the Canadian Thoracic Society and the Mayo Clinic Proceedings 1, 6, 7
LABA monotherapy is an alternative but less preferred option for symptomatic patients, according to the European Respiratory Journal 4, 5
For exacerbation-prone patients (Groups C and D), LAMA monotherapy is preferred over LABA monotherapy, and LAMA/LABA dual therapy is recommended for patients with moderate-to-high symptom burden and impaired lung function, as suggested by the European Respiratory Journal and the Mayo Clinic Proceedings 2, 6, 7

ICS should only be added to LABA (or LAMA/LABA) for patients with blood eosinophil count ≥300 cells/µL, history of ≥2 moderate exacerbations per year despite appropriate long-acting bronchodilator therapy, or history of hospitalizations for COPD exacerbations, as recommended by the Canadian Thoracic Society 1, 8
ACOS patients require at least ICS + LABA, according to the European Respiratory Journal 4, 5
Patients with chronic bronchitis and frequent exacerbations (FEV1 <50% predicted and ≥2 exacerbations per year) may benefit from ICS addition, as reported by the European Respiratory Journal and the American Journal of Respiratory and Critical Care Medicine 4, 5, 9

Patients on LABA monotherapy should be reassessed for symptom control using validated tools (CAT, mMRC) and exacerbation frequency over the subsequent year, as recommended by the Canadian Thoracic Society 1
The need for escalation to LAMA/LABA or consideration of ICS addition should be based on the criteria above, according to the Canadian Thoracic Society and the Mayo Clinic Proceedings 1, 6, 7